Night Sound Device Tested for Sleep and Brain Changes in REM Sleep Disorder
Tests a night sound headband to boost deep sleep in people with REM sleep disorder.
Plain-language title generated from the registry record
Registry title: Role of Slow Waves in the Progression of Neurodegeneration in Isolated REM Sleep Behavior Disorder
Key facts
- Where
- Zurich, SwitzerlandSee the site
Where in Switzerland
- University Hospital Zurich, Neurology DepartmentZurich, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Zurich
- Trial code
- NCT07355842
- Record updated
- 17 February 2026
- Original description
This study tests whether enhancing deep sleep with gentle sounds at night can slow progression in people with iRBD or early Parkinson's disease. Participants wear a sensor headband and headphones for 18 months. Four assessments including mobility, memory, imaging (PET/MRI), lumbar puncture, and blood tests are assessed.Read full original descriptionShow less
Role of Slow Waves in the Progression of Neurodegeneration in Isolated REM Sleep Behavior Disorder
This study tests whether enhancing deep sleep with gentle sounds at night can slow progression in people with iRBD or early Parkinson's disease. Participants wear a sensor headband and headphones for 18 months. Four assessments including mobility, memory, imaging (PET/MRI), lumbar puncture, and blood tests are assessed.
Inclusion: Signed informed consent; Diagnosis of polysomnography-confirmed isolated REM Sleep Behavior Disorder (iRBD) based on international criteria (ICSD-3), combined with EITHER; UPDRS III without action tremor ≥ 4 AND abnormal olfaction, OR; diagnosis of PD along international criteria for less than 2 years; Further inclusion criteria are:; no dopaminergic treatment and no foreseen start of such treatment during duration of the study; ability to apply the intervention, alone or with help of a co-habitant, stable living situation; sufficient language skills in German, French or Italian; negative pregnancy test for women of child-bearing potential.
Exclusion: Suspected or known non-compliance to other therapies; clinically significant concomitant disease or unstable condition; recent or planned major surgery; hearing impairment that prevents hearing the tones for auditory stimulation; Restless Legs Syndrome; meeting criteria for diagnosis of atypical Parkinson syndrome; diagnosis of Dementia or Montreal Cognitive Assessment (MoCA) < 24; severe Depression or other psychiatric disorder; current or recent history within the last year of substance abuse disorders or chronic alcohol consumption; history of allergies and hypersensitivity relevant for electrode application or medication allergies; current or recent participation in another clinical trial; extended absences; non-responder to auditory stimulation during screening; Apnea-Hypopnea-Index (AHI) > 15/h or under Continuous Positive Airway Pressure (CPAP) treatment; regular use of benzodiazepines and other central nervous system depressant substances; additional exclusion criteria for PET imaging; any criterion that may pose the participant at risk; breastfeeding, intention to become pregnant, or unwillingness to use medically reliable contraception for women of child-bearing potential.